Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.53 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.53 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.51 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918279 | 1.00 | NPC1 (0.55) | NPC1RAB9ACA1CA2HPGD | |
| 4-Methoxysalicylic Acid SCHEMBL9277153 | 0.85 | NPC1 (0.70) | NPC1RAB9ACA1CA2HPGD | |
| SCHEMBL9148929 | 0.85 | RAB9A (0.53) | NPC1RAB9AHPGDALDH1A1CYP3A4 | |
| SCHEMBL5346655 | 0.83 | NPC1 (0.53) | NPC1RAB9ACA1CA2HPGD | |
| Zinc Ion SCHEMBL8943602 | 0.82 | MAPT (0.45) | NPC1RAB9ACA1CA2HPGD | |
| SCHEMBL28093168 | 0.82 | RAB9A (0.71) | NPC1RAB9AHPGDALDH1A1CYP3A4 | |
| 4-Methoxysalicylic Acid SCHEMBL154118 | 0.81 | NPC1 (0.70) | NPC1RAB9AHPGDALDH1A1CYP3A4 | |
| SCHEMBL128781 | 0.81 | CA1 (0.61) | NPC1RAB9ACA1CA2HPGD | |
| SCHEMBL29431885 | 0.81 | CA1 (0.61) | NPC1RAB9ACA1CA2HPGD | |
| SCHEMBL6856233 | 0.81 | NPC1 (0.58) | NPC1RAB9ACA1CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118231578-A | Positive electrode plate, battery cell, battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| WO-1995034294-A1 | CONTROLLED RELEASE ORAL DRUG DELIVERY SYSTEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-12-21 | — | — | WO | claimed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | claimed |
| US-4462991-A | POLYPEPTIDE ADJUVANTS OF CARBOXY- OR SULFOSUBSTITUTED PHENOLS | INTERX RESEARCH CORP. (US) | 1984-07-31 | — | — | US | claimed |
| US-4459295-A | Method of increasing oral absorption of glycosidic and related antibiotics | INTERX RESEARCH CORPORATION (US) | 1984-07-10 | — | — | US | claimed |
| EP-4746862-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075448-A | Pharmaceutical composition with enhanced permeation | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026090119-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-4464363-A | HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS | MERCK & CO., INC. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4462991-A | POLYPEPTIDE ADJUVANTS OF CARBOXY- OR SULFOSUBSTITUTED PHENOLS | INTERX RESEARCH CORP. (US) | 1984-07-31 | — | — | US | disclosed |
| US-4459295-A | Method of increasing oral absorption of glycosidic and related antibiotics | INTERX RESEARCH CORPORATION (US) | 1984-07-10 | — | — | US | disclosed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | disclosed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | disclosed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | ADRB1, ADRB2, ADRA1D | CA1 3445/4885CA2 2489/4885ADORA3 171/4885 |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | ICAM1, GJA1, ICOS | CA1 3291/4885CA2 1711/4885ADORA3 1099/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CA1 245/4885CA2 620/4885ADORA3 4503/4885 |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRB1, ADRB2, ADRA1D | CA1 4310/4885CA2 4080/4885ADORA3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.